Document:

ex10_7.htm

  

    Exhibit
10.7

    

    ANNUAL
BONUS PLAN FOR EXECUTIVE OFFICERS

    EMERGENT
BIOSOLUTIONS INC.

    ADOPTED
FEBRUARY 25, 2010

    

    

    Annual
bonuses to be awarded to the chief executive officer (“CEO”), president and
chief operating officer (“President”) and other executive officers of Emergent
BioSolutions Inc. (“Company”) shall be made in accordance with the terms and
conditions of the Company’s Annual Bonus Plan for Executive Officers
(“Plan”).  The Plan is not the exclusive vehicle for awarding bonuses
to executive officers.  The Committee may also make discretionary
bonuses outside of the framework of the Plan.  The Plan is not
contained in a formal written document; however, a summary of the material terms
of the Plan is set forth below.

    

    Each
participant’s annual bonus under the Plan will be determined by multiplying the
participant’s annual base salary by (a) a target bonus percentage for such
participant, (b) a corporate factor ranging from 0 to 1.5, based on the
Company’s achievement of corporate goals determined by the Committee, and (c) an
individual factor ranging from 0 to 1.5, based on an evaluation of each
participant’s performance of day-to-day responsibilities, behavioral
competencies, and participation in the achievement of the corporate goals and
achievement of individual goals determined by the Committee. The Plan will apply
to bonuses that are earned in 2010 and are payable in 2011, and for each year
thereafter.

    

    The
Company’s corporate goals will be set at the beginning of each year by the
Committee, based on recommendations by the Company’s management.  At
the end of the year, the Committee will determine the corporate factor based on
a quantitative and qualitative review of performance.  Each
participant’s individual goals will be set at the beginning of each
year.  A year-end evaluation of each participant may weight individual
goals, and the applicable individual factor will be determined based on a
quantitative and qualitative review of performance.  The Committee’s
chair will recommend the CEO’s individual goals and individual factor to the
Committee, the CEO will recommend the President’s individual goals and
individual factor to the Committee, and the CEO and President will recommend the
individual goals and individual factor of each other Plan participant to the
Committee.  All individual goals and individual factors will be set by
the Committee.ex10_18.htm

  

     

    EXHIBIT
10.18

    
      
        	
                 CONFIDENTIAL MATERIALS OMITTED
      AND FILED SEPERATLY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
      

                ASTERISK DENOTE
      OMISSIONS. 

              

      

       

    

     

     

    Talecris

    BIOTHERAPEUTICS

    

    AMENDMENT
NO. 1 to the

    

    PRODUCT
SUPPLY AGREEMENT

    

    This
Amendment No. 1 (the "Amendment"), effective as of December 19, 2006 (the
“Effective Date”), is entered into by and between Talecris Biotherapeutics,
Inc., headquartered at 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box
110526, Research Triangle Park, North Carolina 27709 ("Talecris") and Emergent
Product Development Gaithersburg Inc. ("Emergent" collectively, with Talecris,
the "Parties," and each individually, a "Party"). All terms not defined herein
shall have the meaning set forth in the Master Agreement (as defined
below).

    

    WHEREAS,
the Parties entered into that certain Product Supply Agreement, effective as of
June 12, 2006 (the "Master Agreement');

    

    WHEREAS
the Parties desire to amend and restate the Master Agreement as set forth herein
to modify the requirements for stability testing of the AIG Product and the
payment schedule for the testing; and;

    

    WHEREAS,
except as specifically modified herein, the Master Agreement, as amended by this
Amendment, shall remain in full force and effect.

    

    NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants herein
contained, the Parties hereto agree as follows:

    

    1. Amendment of Article 7.02,
Fees Associated With Certain Pre-Commercial Activities, Subpart B Stability
Testing. Article 7.02, Subpart B of the Master Agreement is hereby
deleted in its entirety and replaced with:

    

    "Emergent
shall pay Talecris following Talecris' performance of stability testing,
(approved stability protocol attached) and related activities in accordance with
Exhibit L,.
attached hereto and incorporated by reference into the Master
Agreement.

    

    2. Applicable Law. This
Amendment, and the amended Agreement, shall be governed by the laws of the State
of Delaware without regard to any conflicts of law principles.

    

    

    IN
WITNESS WHEREOF, the Parties have executed this Amendment as set forth
below.

    

    

    

    

    TALECRIS
BIOTHERAPEUTICS,
INC.                                                                                     EMERGENT
PRODUCT DEVELOPMENT

    GAITHERSBURG INC.

    

    By:             /s/ Mary J
Kuhn                                                          By:             /s/ M J
Langford 

    

    Name:        Mary
J.
Kuhn                                  Name:      Michael
J. Langford

    

    Title:           SVP
Operations                                                          Title:         President

    

    

    

    
      
         

      

      
         

         

      

      
         

      

    

    Exhibit
L

    

    

    Payment
schedule for Amended Stability Protocol

    

    
      	
              Purpose:

            	
              Emergent
      has requested a greater amount of stability testing than is stated in the
      original contract. The original contract required 15 test points to be
      done on three product lots. The price was $[**] dollars to perform the
      45-test point study. The stability protocol now requested requires 24 test
      points to be done on 3 AIG product lots. This increases the total number
      of test points to 72 test points which is an increase of 27 test points.
      The approved protocol is follows.

            

    

    

    Calculations:

    
      	
              Talecris
      Cost to perform the

              requested
      protocol (3 lots)

            	 	$	[**]	 
	
              #
      of Test Points per lot

            	 	 	24	 
	
              #
      of Test Points for 3 lots

            	 	 	72	 
	
              Cost
      per test Point

            	 	$	[**]	 
	
              #
      of test points of original

            	 	 	15	 
	
              Stability
      schedule per lot

            	 	 	 	 
	
              #
      of test points for 3 lots

            	 	 	45	 
	
              Original
      agreement for

            	 	$	[**]	 
	
              Stability
      Protocol

            	 	 	 	 
	
              Additional
      test points

              required

            	 	 	27	 
	
              Cost
      to perform additional

              test
      points

            	 	$	[**]	 
	
              Total
      revised Charge to

            	 	$	[**]	 
	
              Emergent
      for study

            	 	 	 	 

    

    

     

     

    
      	
              Invoice
      Timing:

            	
              The
      study is requested for 5 years. Talecris will invoice Emergent for 20% of
      the total price each year when the annual report is
  issued.ex10_19.htm

  

    Exhibit
10.19

    Talecris

    BIOTHERAPEUTICS

    

     

    AMENDMENT
NO. 2 to the

     

     

    Product
Supply Agreement

     

    

     

    This
Amendment No. 2 (the "Amendment"), effective as of June 25, 2007 (the "Effective
Date"), is entered into by and between Talecris Biotherapeutics, Inc.,
headquartered at 79 T.W. Alexander Drive, 4101 Research Commons, P.O. Box
110526, Research Triangle Park, North Carolina 27709 ("Talecris") and Emergent
Product Development Gaithersburg Inc. with an address of 300 Professional Drive,
Gaithersburg, MD 20879 ("Emergent" collectively, with Talecris, the "Parties,"
and each individually, a "Party"). All terms not defined herein shall have the
meaning set forth in the Master Agreement (as defined below).

     

    WHEREAS,
the Parties entered into that certain Product Supply Agreement, effective as of
June 12, 2006 (the "Master Agreement");

     

     

    WHEREAS
the Parties desire to amend and restate the Master Agreement as set forth
herein; and;

     

    WHEREAS,
except as specifically modified herein, the Master Agreement, as amended by this
Amendment, shall remain in full force and effect.

     

    NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants herein
contained, the Parties hereto agree as follows:

     

    1. Amendment of Section 7.06,
Method of Invoicing for Orders. Section 7.06 of the Master Agreement is
hereby amended by adding the following sentence;

     

    "Provided
however, Talecris may, at its discretion, invoice Emergent for an Order based
solely on; (a) Talecris' determination that Product release testing has been
met, and (b) the required samples were provided to Emergent by Talecris, within
three (3) days of packaging of product by Talecris, and (c) Emergent has not
provided identity test results to Talecris, within thirty-five (35) days of
packaging of the product."

     

    2. Amendment of Section 7.07,
Remittance of Payments. Section 7.07 of
the Master Agreement is hereby amended by deleting section 7.07 entirely and
replacing with the following:

     

    a. Timing. Payments due
by Emergent under this Article 7 shall be payable by Emergent no later than
thirty (30) days after the invoice date; provided, however, that the Finished
Product associated with such payment was actually delivered in compliance with
Section 6.01. Notwithstanding the foregoing, if Emergent has not made
arrangements for and obtained the delivery of (i) Finished Product within thirty
(30) days of receipt of an invoice into either (a) the custody of Emergent's
carrier, or (b) onsite storage at Talecris Facilities subject to any applicable
Fees mutually agreed to by the Parties, or (ii) product which meets the Product
Specifications (subject to Section 7.06), payment shall be due and payable by
Emergent promptly.

     

    b. Method of Payment.
Emergent shall make payment by wire transfer of Dollars to a bank account
designated by Talecris or by such other payment method as the Parties may agree
upon from time to time."

     

    3. Applicable Law. This
Amendment, and the amended Agreement, shall be governed by the laws of the State
of New York, without regard to any conflicts of law principles.

     

    IN
WITNESS WHEREOF, the Parties have executed this Amendment as set forth
below.

    

     

    TALECRIS
BIOTHERAPEUTICS,
INC.                                                                     EMERGENT
PRODUCT DEVELOPMENT GAITHERSBURG INC

    

    

    By:         
   /s/  Mary
J.
Kuhn                                                                                      
 By:            /s/ M J
Langford 

     

    Name:      Mary
J.
Kuhn                                               Name:    Michael
Langford

     

           
Title:        SVP
Operations                                                                 
Title:      President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]